MaxiVAX raised €4.6M in a Series B round in Oct 2019. The company is based in Geneva, Switzerland. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
No investors disclosed for this round.
This is the company's only recorded round.
